GeNeuro SA

New publication shows that "HERV expression profiles robustly associated with #ALS amyotrophic lateral sclerosis and #MS multiple sclerosis. This supports GeNeuro's therapeutic strategy against these diseases by targeting #HERV https://lnkd.in/epFDRWKe

Prof. Patrick Kuery’s team from Heinrich-Heine-University presented exciting new data at ECTRMIS 2024 that provides the capping stone for the concept of the anti-neurodegenerative effect of temelimab in an #MS model. This new model closely replicates the neurodegenerative mechanisms observed in MS, which are believed to be key drivers of long-term disability progression. When transgenic animals are treated in the periphery with the antibody, demyelination, neurodegeneration as well as microglial and astroglial polarization are rescued. GeNeuro is striving to secure a partnership to advance the development of #temelimab against #neurodegeneration in MS in combination with anti-inflammatory treatments, despite facing financial challenges. https://lnkd.in/eA3pJmAP

Today we announced that the clinical trial against #postCOVID did not meet its primary endpoint. While these results are disappointing, GeNeuro will continue to analyze the data thoroughly to understand the results and explore potential insights.   GeNeuro thanks all the study participants, the investigators and all other site personnel for their commitment that made this novel study possible. The learnings from this study will certainly advance the knowledge of this new disease affecting millions of persons worldwide. https://lnkd.in/eqi8zXzg

GeNeuro is determined to develop GNK-301, an antibody designed to neutralize the #HERV-K ENV neurotoxin, which has been detected in the cerebrospinal fluid of patients with sporadic #ALS. This development is driven by the urgent need for effective treatments and the potential impact GNK-301 could have on improving patient outcomes. #ALS Awareness Day

New article from @kuerypatrick and team showing that W-ENV activates brain microglia and astrocytes fueling #smoulderingMS #temelimab, the anti #HERV W-ENV antibody developed by GeNeuro, has shown benefits on brain atrophy, myelin integrity and GAFP in #MS Phase II trials. https://lnkd.in/eYn9xp9s

Further evidence that #longcovid is a major public health problem affecting millions of patients #covidpersistente #postcovid #PASC https://lnkd.in/e_-PNv87

Congratulations to Patric Küry and team for their important article showing the effects of HERV-W on #MS-related smoldering neuroinflammation. #smolderingMS #HERVs https://lnkd.in/dei54MKE

Interesting article comparing cognitive and fatigue symptoms in #MS and #postCOVID patients. #HERV-W ENV has been found to be activated in both pathologies. #LongCovid #Covidpersistente #neurodegeneration https://lnkd.in/enYBgY7S

Further evidence on the important role of #HERV-W ENV in #MS #temelimab https://lnkd.in/eg72q4MC